Optimizing emetic control in children receiving antineoplastic therapy: Beyond the guidelines

Pediatric Drugs

Volumn 12, Issue 1, 2010, Pages 51-61

  Lee Dupuis, L ^a,b,c   Nathan, Paul C ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acupressure; Acupuncture; Antiemetics, therapeutic use; Antineoplastics, therapeutic use; Aprepitant, therapeutic use; Chemotherapy induced nausea and vomiting, treatment; Children; Corticosteroids, therapeutic use; Dexamethasone, therapeutic use

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DROPERIDOL; EMETIC AGENT; FOSAPREPITANT; GABAPENTIN; GRANISETRON; LORAZEPAM; METOPIMAZINE; MIDAZOLAM; MIRTAZAPINE; NABILONE; OLANZAPINE; ONDANSETRON; PALONOSETRON; RETINOL; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ABSENCE OF SIDE EFFECTS; ACUPRESSURE; ACUPUNCTURE; BEDTIME DOSAGE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ECG ABNORMALITY; ELECTROACUPUNCTURE; ELECTROCARDIOGRAM; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

ACUPUNCTURE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; GLUCOCORTICOIDS; GUIDELINE ADHERENCE; HEADACHE; HUMANS; NAUSEA; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 73849111592     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11316190-000000000-00000     Document Type: Review

References (97)

1. Roila F, Feyer P, Maranzano R, et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 2005; 13: 129-131
2. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947
3. Robson H, Meyer S, Shalet S, et al. The anti-tumor effects of cytotoxics are modulated by glucocorticoids in human osteosarcoma in vitro [abstract]. Med Pediatr Oncol 1999; 33: 155
4. Weller M, Schmidt C, Roth W, et al. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 1997; 48: 1704-1709
5. Rieger J, Durka S, Streffer J, et al. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 1999; 365: 301-308
6. Mariotta M, Perewusnyk G, Koechli OR, et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol 1999; 175: 392-396
7. Straathof CS, van den Bent MJ, Ma J, et al. The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neurooncol 1998; 37: 1-8
8. Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011-1015
9. Hochhauser CJ, Lewis M, Kamen BA, et al. Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia. Support Care Cancer 2005; 13: 967-974
10. Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19: 667-687
11. Marr KA, Carter RA, BoeckhM, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366
12. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21: 209-211
13. Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receivingmethylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328-1332
14. Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 2002; 17: 857-858
15. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278-282
16. Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005; 28: 201-204
17. Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47: 567-571
18. Coppes MJ, Yanofsky R, Pritchard S, et al. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetronmesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 1999; 21: 274-283
19. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy [published erratum appears in Support Care Cancer 2005 Jul; 13 (7): 562]. Support Care Cancer 2005; 13: 85-96
20. Antonarakis ES, Evans JL, Heard GF, et al. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence? Pediatr Blood Cancer 2004; 43: 651-658
21. Bleiberg H, Van Belle S, Paridaens R, et al. Compassionate use of a 5-HT3- receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment. Drugs 1992; 43 Suppl. 3: 27-32
22. Gershanovich M, Kolygin B, Pirgach N. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 1993; 4 Suppl. 3: 35-37
23. Hachimi-Idrissi S, De Schepper J, Maurus R, et al. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 854-856
24. Suarez A, Stettler ER, Rey E, et al. Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy. Eur J Cancer 1994; 30A: 1436-1441
25. Rosso P, Cordero di Montezemolo L, Vivenza C, et al. Efficacy of tropisetron (Navoban) in controlling emesis induced in children by anti-cancer therapy. Tumori 1994; 80: 459-463
26. Benoit Y, Hulstaert F, Vermylen C, et al. Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy. Anticancer Drugs 1995; 6 Suppl. 1: 9-14
27. Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 1999; 16: 101-108
28. Uysal KM, Olgun N, Sarialioglu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Pediatr 1999; 41: 207-218
29. Aksoylar S, Akman SA, Ozgenc F, et al. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 2001; 18: 397-406
30. Cappelli C, Ragni G, De Pasquale MD, et al. Tropisetron: optimal dosage for children in prevention of chemotherapy-induced vomiting. Pediatr Blood Cancer 2005; 45: 48-53
31. Forni C, Ferrari S, Loro L, et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatinadriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 2000; 8: 131-133
32. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-2811
33. Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147-2155
34. Gralla RJ, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577
35. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor anagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482
36. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-1300
37. Adel N, Lucarelli C, Khan A, et al. Evaluating the use of palonosetron in pediatric patients for the prevention of chemotherapy induced nausea and vomiting (CINV). 40th Midyear Clinical Meeting of the American Society of Health-System Pharmacists; 2005 Dec 4-8; Las Vegas (NV)
38. Kadota R, Shen V, Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study [abstract]. J Clin Oncol 2007; 25 Suppl.: 9570
39. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multi-national, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119
40. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: 857-860
41. Vianello O, Manfredini L, Miano M, et al. Effect of aprepitant on antiemetic protection in adolescents with cancer receiving highly emetogenic chemotherapy: a preliminary experience [abstract]. Support Care Cancer 2005; 13: 422
42. Ouellet G, Therrien R. Utilisation de l'aprepitant pour les nausees et les vomissements refractaires secondaires a la chimiotherapie chez une adolescente. Pharmactuel 2005; 38: 220-225
43. Gore L, Chawla SP, Petrilli AS, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52: 242-247
44. Murphy C, Shah N, Milla P, et al. NK1 receptor antagonism ameliorates nausea and emesis in typical and atypical variants of treatment refractory cyclical vomiting syndrome [abstract]. J Pediatr Gastroenterol 2006; 42: E13-4
45. Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer 2009; 17: 701-706
46. Merck Frosst Canada Ltd. Product monograph: Emend- aprepitant capsules 80 and 125 mg [online]. Available from URL: http://www.merckfrosst.ca/ assets/en/pdf/products/EMEND-0810-a-124638-E.pdf. [Accessed 2009 Nov 30]
47. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55: 609-616
48. Herrstedt J, Sigsgaard T, Boesgaard M, et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-1080
49. Herrstedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 1997; 15: 1690-1696
50. Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007; 15: 417-426
51. Lebeau B, Depierre A, Giovannini M, et al. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Ann Oncol 1997; 8: 887-892
52. Bloch J, Rixe O, Meric JB, et al. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 2005; 21: 1763-1771
53. Khamales S, Bethune-Volters A, Chidiac J, et al. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs 2006; 17: 217-224
54. Nathan PC, Tomlinson G, Dupuis LL, et al. A pilot study of ondansetron plus metopimazine versus ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer 2006; 14: 268-276
55. Debray H, Guihard J, Peyramond D, et al. Traitement des vomissements du nourrisson et de l'infant lies a une pathologie infectieuse aigue. Ann Pediatr (Paris) 1990; 37: 683-687
56. Jones E, Koyama T,Ho RH, et al. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Pediatr Blood Cancer 2007; 48: 330-332
57. Dix S, Cord M, Howard S, et al. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Bone Marrow Transplant 1999; 24: 561-566
58. Olsen E, Thompson A. Unique anti-emetic management in the pediatric bone marrow transplant patients [abstract]. J Pediatr Hematol Oncol 2005; 27: 462
59. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16-21
60. Davis M, Maida V, Daeninck P, et al. The emerging role of cannabinoid neuromodulators in syptom management. Support Care Cancer 2007; 15: 63-71
61. Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatr Drugs 2003; 5: 597-613
62. Parfitt A. Acupuncture as an antiemetic treatment. J Altern ComplementMed 1996; 2: 167-74, discussion 175-177
63. Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J R Soc Med 1996; 89: 303-311
64. Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006; (2): CD002285
65. Molassiotis A, Helin AM, DabbourR, et al. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complement Ther Med 2007; 15: 3-12
66. Reindl TK, Geilen W, Hartmann R, et al. Acupuncture against chemotherapyinduced nausea and vomiting in pediatric oncology: interim results of a multicenter crossover study. Support Care Cancer 2006; 14: 172-176
67. Jones E, Isom S, Kemper KJ, et al. Acupressure for chemotherapy- associated nausea and vomiting in children. J Soc Integr Oncol 2008; 6: 141-145
68. Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000; 9: 84-87
69. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25: 578-582
70. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003; 25: 485-488
71. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526-532
72. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investigation 2004; 22: 383-388
73. Navari RM, Einhorn LH, Loehrer Sr PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapyinduced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 2007; 15: 1285-1291
74. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40: 887-894
75. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22: 455-460
76. Guttuso Jr T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361: 1703-1705
77. Pandey CK, Priye S, Ambesh SP, et al. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. J Postgrad Med 2006; 52: 97-100
78. Ho KY. Gabapentin for postoperative nausea and vomiting prophylaxis. J Postgrad Med 2006; 52: 230-231
79. Mandala M, Cremonesi M, Rocca A, et al. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 2005; 13: 375-380
80. Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1143-1145
81. Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006; 47: 440-442
82. Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003; 268: 219-221
83. Guclu S, Gol M, Dogan E, et al. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005; 272: 298-300
84. Caldis EV, Gair RD. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors [letter]. Can J Psychiatry 2004; 49: 707
85. Teixeira FV, Novaretti TM, Pilon B, et al. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg 2005; 15: 707-709
86. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23: 442-447
87. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41: 356-359
88. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 2007; 16: 351-354
89. Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001; 11: 267-277
90. Albertini G, Polito E, Sara M, et al. Compulsive masturbation in infantile autism treated by mirtazapine. Pediatr Neurol 2006; 34: 417-418
91. Haapasalo-Pesu KM, Vuola T, Lahelma L, et al. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol 2004; 14: 175-184
92. Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006; 16: 131-145
93. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-1696
94. Lewis GO, Bernath AM, Ellison NM, et al. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy. Clin Pharmacy 1984; 3: 618-621
95. Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. Eur J Cancer Clin Oncol 1986; 22: 1199-1203
96. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107: 531-536
97. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9: 811-819